Understanding biosimilars – and communicating with patients about them – is a key asset for rheumatologists and their delivery of care. UR is committed to helping members remain updated on biosimilars and how these biological products can treat rheumatologic diseases. The Food and Drug Administration is a leading source of information for providers.
Biosimilar Product Regulatory Review and Approval is an FDA backgrounder about biosimilars that can be helpful for offices to understand and share with interested patients.